Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques

Neurobiology of Disease

Volumn 71, Issue , 2014, Pages 53-61

  Pensalfini, Anna ^a,d   Albay, Ricardo ^a   Rasool, Suhail ^a,e   Wu, Jessica W ^a,f   Hatami, Asa ^a,g   Arai, Hiromi ^a   Margol, Lawrence ^a   Milton, Saskia ^a   Poon, Wayne W ^b   Corrada, Maria M ^b   Kawas, Claudia H ^b   Glabe, Charles G ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Department of Medicine   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer; Intracellular amyloid; Neuritic plaques; Nuclear pathology

Indexed keywords

ALPHA SYNUCLEIN; AMYLIN; AMYLOID; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CARBOXYL TERMINAL AMYLOID PRECURSOR PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M78; NEURON SPECIFIC NUCLEAR PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ENOLASE; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BIOACCUMULATION; CELL LEVEL; CELL NUCLEUS; CHROMATIN; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN UNFOLDING; SENILE PLAQUE; VERY ELDERLY; AGE; ANIMAL; BRAIN; CYTOPLASM; DISEASE MODEL; GENETICS; METABOLISM; NERVE CELL; NUCLEOLUS; PATHOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CELL NUCLEOLUS; CYTOPLASM; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEURONS; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84906551274     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.07.011     Document Type: Article

References (40)

1. Arai H., Lee V.M., et al. Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques. Proc. Natl. Acad. Sci. U. S. A. 1990, 87(6):2249-2253.
2. Bentahir M., Nyabi O., et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 2006, 96(3):732-742.
3. Braak H., Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991, 1(3):213-216.
4. Cacquevel M., Aeschbach L., et al. Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified gamma-secretase complexes. PLoS One 2012, 7(4):e35133.
5. Citron M., Westaway D., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 1997, 3(1):67-72.
6. Corrada M.M., Berlau D.J., Kawas C.H. A population-based clinicopathological study in the oldest-old: the 90+study. Curr. Alzheimer Res. 2012, 9(6):709-717.
7. Cummings B.J., Su J.H., et al. Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease. Neuroscience 1992, 48:763-777.
8. Cummings B.J., Mason A.J., et al. Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol. Aging 2002, 23(2):161-170.
9. D'Andrea M.R., Nagele R.G., et al. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 2001, 38(2):120-134.
10. Doody R.S., Raman R., et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 2013, 369(4):341-350.
11. Ferretti M.T., Partridge V., et al. Transgenic mice as a model of pre-clinical Alzheimer's disease. Curr. Alzheimer Res. 2011, 8(1):4-23.
12. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283(44):29639-29643.
13. Gouras G.K., Tsai J., et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156(1):15-20.
14. Grundke-Iqbal I., Iqbal K., et al. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:2853-2857.
15. Hu X., Shi Q., et al. Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities. EMBO J. 2007, 26(11):2755-2767.
16. Ikeda S., Allsop D., et al. A study of the morphology and distribution of amyloid beta protein immunoreactive plaque and related lesions in the brains of Alzheimer's disease and adult Down's syndrome. Prog. Clin. Biol. Res. 1989, 317:313-323.
17. Joachim C., Games D., et al. Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. Am. J. Pathol. 1991, 138:373-384.
18. Jonsson T., Atwal J.K., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488(7409):96-99.
19. Kayed R., Head E., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300(5618):486-489.
20. Kayed R., Head E., et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2007, 2(18):18.
21. Kayed R., Pensalfini A., et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem. 2009, 284(7):4230-4237.
22. Kayed R., Canto I., et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Mol. Neurodegener. 2010, 5:57.
23. Kulic L., McAfoose J., et al. Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Abeta APP mutation. Transl. Psychiatry 2012, 2:e183.
24. McLean D., Cooke M.J., et al. Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-beta in TgCRND8 mice. ACS Chem. Neurosci. 2013, 4(4):613-623.
25. Necula M., Kayed R., et al. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 2007, 282(14):10311-10324.
26. Nussbaum J.M., Schilling S., et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 2012, 485(7400):651-655.
27. Oddo S., Caccamo A., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39(3):409-421.
28. Oddo S., Caccamo A., et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 2006, 281(3):1599-1604.
29. Perry G., Siedlak S., et al. Immunolocalization of the amyloid precursor protein within the senile plaque. Prog. Clin. Biol. Res. 1989, 317:1021-1025.
30. Rasool S., Albay R., et al. Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. Mol. Neurodegener. 2012, 7:37.
31. Robakis N.K. Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives. Neurobiol. Aging 2011, 32(3):372-379.
32. Schmitz C., Rutten B.P., et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 2004, 164(4):1495-1502.
33. Selkoe D.J., Podlisny M.B., et al. Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:7341-7345.
34. Stern R.A., Otvos L., et al. Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system. Am. J. Pathol. 1989, 134:973-978.
35. Terry R.D. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 1996, 55(10):1023-1025.
36. Thal D.R., Rub U., et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58(12):1791-1800.
37. Tomic J.L., Pensalfini A., et al. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 2009, 35(3):352-358.
38. Wartha F., Henriques-Normark B. ETosis: a novel cell death pathway. Sci. Signal. 2008, 1(21):pe25.
39. Winton M.J., Lee E.B., et al. Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: implications for tau versus Abeta-mediated Alzheimer neurodegeneration. J. Neurosci. 2011, 31(21):7691-7699.
40. Wirths O., Bayer T.A. Intraneuronal Abeta accumulation and neurodegeneration: lessons from transgenic models. Life Sci. 2012, 91(23-24):1148-1152.